Liquidia (NASDAQ:LQDA) Director Sells $9,571,663.32 in Stock

Liquidia Corporation (NASDAQ:LQDA) Director Stephen Bloch sold 145,954 shares of Liquidia stock in a transaction on Wednesday, June 10th. The stock was sold at an average price of $65.58, for a total value of $9,571,663.32. Following the sale, the director directly owned 1,418,453 shares of the company’s stock, valued at $93,022,147.74. This represents a 9.33% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Liquidia Price Performance

LQDA opened at $71.23 on Monday. Liquidia Corporation has a fifty-two week low of $11.85 and a fifty-two week high of $72.71. The company has a debt-to-equity ratio of 1.18, a quick ratio of 2.03 and a current ratio of 2.22. The company has a market capitalization of $6.33 billion, a P/E ratio of 508.82 and a beta of 0.57. The stock has a fifty day moving average of $49.85 and a 200-day moving average of $40.96.

Liquidia (NASDAQ:LQDA) last posted its earnings results on Monday, May 11th. The company reported $0.52 earnings per share for the quarter, topping analysts’ consensus estimates of $0.41 by $0.11. Liquidia had a return on equity of 46.82% and a net margin of 7.74%.The company had revenue of $132.87 million during the quarter, compared to the consensus estimate of $119.44 million. The business’s quarterly revenue was up 4187.1% compared to the same quarter last year. On average, equities analysts expect that Liquidia Corporation will post 2.97 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the stock. Seven Fleet Capital Management LP increased its position in shares of Liquidia by 124.5% in the first quarter. Seven Fleet Capital Management LP now owns 204,876 shares of the company’s stock worth $7,732,000 after purchasing an additional 113,609 shares during the period. Segall Bryant & Hamill LLC bought a new position in shares of Liquidia in the first quarter worth $2,111,000. Bank of America Corp DE increased its position in shares of Liquidia by 18.7% in the first quarter. Bank of America Corp DE now owns 2,287,792 shares of the company’s stock worth $86,341,000 after purchasing an additional 360,372 shares during the period. California State Teachers Retirement System increased its position in shares of Liquidia by 25.0% in the first quarter. California State Teachers Retirement System now owns 72,438 shares of the company’s stock worth $2,734,000 after purchasing an additional 14,485 shares during the period. Finally, Empowered Funds LLC bought a new position in Liquidia in the first quarter valued at about $3,650,000. Institutional investors own 64.54% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on LQDA shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Liquidia in a report on Tuesday, April 21st. Wall Street Zen upgraded Liquidia from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 16th. Oppenheimer set a $75.00 price target on Liquidia in a research report on Friday, June 5th. HC Wainwright raised their price target on Liquidia from $67.00 to $75.00 and gave the stock a “buy” rating in a research report on Friday, June 5th. Finally, Needham & Company LLC raised their price target on Liquidia from $54.00 to $70.00 and gave the stock a “buy” rating in a research report on Monday, May 11th. Three research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Liquidia presently has a consensus rating of “Moderate Buy” and an average target price of $60.29.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).